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Hypoxic cells present in many solid tumours can limit tumour cure
by ionizing radiation and perhaps by some drugs (Bush et al, 1978;
Overgaard, 1994; Hockel et al, 1996; Fyles et al, 1998). Detecting
hypoxic tumour cells at the start of therapy would provide an
opportunity to include treatment strategies designed to improve
tumour oxygenation or kill hypoxic tumour cells (Brown and
Giaccia, 1998). Pimonidazole is known to be preferentially bound
by hypoxic tumour cells, so detection of pimonidazole adducts
using monoclonal antibodies can serve as a method for measuring
tumour hypoxia (Thrall et al, 1997; Raleigh et al, 1999). Clinical
trials of pimonidazole binding in human tumours are currently
underway in the US, Canada and Europe, with the goal of deter-
mining whether this marker can be used to predict tumour
response to radiation (Kennedy et al, 1997; Varia et al, 1998).
Although most efforts have been directed toward analysis of anti-
body binding in tumour sections, flow cytometry should also be
applicable. Flow cytometry offers certain advantages over static
cytometry in terms of speed of analysis, removal of necrotic cells,
and potential for multi-parameter analyses. However, the exact
percentage of radiobiologically hypoxic cells can be difficult to
estimate from flow histograms because hypoxia marker binding in
single cells is typically seen as a continuum (Lee et al, 1996;
Durand and Raleigh, 1998; Kavanagh et al, 1999).
Further complications arise from the fact that different tumours
metabolize and bind pimonidazole at different rates, and in the
clinical situation, it is difficult to determine the optimal dose for
best visualizing the hypoxic cells of a particular tumour. This was
recognized in a previous study where the number of cells with
pimonidazole adducts exceeding an arbitrary threshold was found
to correlate exactly with cellular radiosensitivity only when
labelling was optimized (Durand and Raleigh, 1998). However, it
was also noted in that study that those tumours with higher levels
of hypoxia could be identified even with non-optimal labelling
concentrations of pimonidazole, which in turn suggests that a more
rigorous and objective analysis of the flow histograms might be
useful.
Since the ultimate variable of interest is the number of radio-
biologically hypoxic cells, and since the alkaline comet assay can
detect those cells (Olive and Durand, 1992; Olive et al, 1997) even
in the clinic (Olive et al, 1993; McLaren et al, 1997; Aquino-
Parsons et al, 1999), we postulated that the comet assay could be
used to ‘calibrate’ the analysis of pimonidazole histograms
obtained with flow cytometry. A unique advantage of the comet
assay is that the relation between oxygen concentration and 
radiation-induced DNA single-strand breaks is known to be iden-
tical to the relation between oxygen concentration and radiation-
induced cell killing (Chapman et al, 1974; Zhang et al, 1995).
Since both the comet assay and pimonidazole binding can easily
be assessed in any population of single cells, it is possible to
directly compare the two methods. A murine tumour and two
human tumour xenografts were therefore examined using both
comet and pimonidazole marker binding under a range of tumour
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oxygenations produced by breathing different gas mixtures. From
these data, we developed an iterative curve-fitting procedure to
objectively estimate the radiobiologically hypoxic fraction of cells
from the pimonidazole binding distributions. The fitting method-
ology also appeared practical for biopsies in an initial series from
cervical cancer patients who had received pimonidazole.
MATERIALS AND METHODS
Cells and tumours
Chinese hamster V79-171b cells were maintained in exponential
growth by subcultivating twice weekly in minimal essential
medium containing 10% fetal bovine serum. SCCVII squamous
cell carcinoma cells were transplanted subcutaneously over the
sacral region of inbred male C3H/HeN mice, approximately 30 g
in weight. U87 glioma cells and SiHa cervical carcinoma cells
were implanted subcutaneously in the back of NOD/SCID mice
(106 cells/mouse in 0.1 ml phosphate buffered saline (PBS)).
Tumours were used for experimentation 2–4 weeks later when
they had reached a weight of approximately 400 mg.
Mice were injected intraperitoneally with 100 mg kg–1
pimonidazole (Hypoxyprobe-1, Natural Pharmacia International,
Inc., Belmont, MA) from a stock solution of 20 mg ml–1 in sterile
PBS. For 5 minutes before and until time of sacrifice, mice
breathed various humidified gas mixtures in a chamber supplied at
a flow rate of 1.5 l min–1: 100% O2, carbogen (95% O2, 5% CO2),
452 ppm CO, or 10% O2 in N2. Alternatively, mice were injected
with 5 mg kg–1 hydralazine intravenously 15 min after administra-
tion of pimonidazole, or tumours were clamped 20 min after i.p
injection of pimonidazole. 90 min after intraperitoneal injection of
pimonidazole, corresponding to 3 plasma half-lives for this drug
(Walton et al, 1989), mice were exposed to 12 Gy of 250 kV 
X-rays, immediately sacrificed, and the tumours excised within
1 min and placed in ice-cold PBS. A single cell suspension was
prepared from the entire tumour by mincing in ice-cold PBS and
filtering through 30 µ m nylon mesh. Part of this suspension was
used for the comet assay, and the remainder was incubated for
30 min at 37˚C with a mixture of trypsin, collagenase and DNAse
as described previously (Olive, 1989). Cells were then filtered
through 30 µ m nylon mesh, centrifuged and resuspended in cold
PBS. Cells were fixed in 70% ethanol and refrigerated overnight or
up to several days before analysis of pimonidazole binding.
Hoechst 33342 sorting of tumour cells
To examine pimonidazole binding in tumour cells as a function of
their position relative to the functional vasculature, mice were
injected intravenously with Hoechst 33342 20 min before sacri-
fice. Single cells from these tumours were then sorted on the basis
of the Hoechst concentration gradient, as previously described
(Olive, 1995).
Analysis of pimonidazole binding in cervical tumours
Three patients with histologically confirmed locally advanced
cervical cancer consented to undergo an excision biopsy after
pimonidazole administration. For examination of tumour hypoxia,
1.0 g of Hypoxyprobe-1 was dissolved in 100 ml of 0.9% sterile
saline at room temperature, and 0.5 g m–2 was delivered as an
intravenous infusion over about 20 min. Approximately 24 h later
(about 4 plasma half-lives), a small excision biopsy was obtained.
Biopsies were minced and incubated with trypsin, collagenase and
DNAse for 30 minutes to provide a single cell suspension. Cells
were filtered through 30 µ m pore nylon mesh, suspended in PBS,
and diluted with 95% ethanol to a 70% solution. Fixed cells were
analysed for pimonidazole binding (generally within 2 weeks) as
described below. Delayed analysis (up to 2 weeks) was not found
to influence the percentage of hypoxic cells measured using flow
cytometry.
Flow cytometry analysis of pimonidazole binding
Ethanol-fixed cells were rinsed in phosphate buffer then resus-
pended in PST (PBS containing 4% serum and 0.1% triton 
X- 100). A fluorescein isothiocyanate (FITC)-conjugated (1:1000
dilution) or unconjugated (1:100 dilution) primary antibody were
incubated with 2 × 106 alcohol-fixed cells for 2 h at 37˚C (for anti-
body source and description, see Raleigh et al (1999)). Samples
were rinsed in PST and those cells that were incubated with the
unconjugated primary were resuspended in a FITC conjugated
secondary antibody diluted 1:100 in PST for 1 h at 37˚C. Samples
were rinsed in PST and resuspended for DNA staining in 1 ml PBS
containing 1 µ g ml–1 4,6-diamidino-2-phenylindole dihydro-
chloride hydrate (DAPI). Samples were analysed on a Coulter
Epics Elite cell sorter (Coulter Corp. Hialeah, FL). Approximately
20 000 cells were acquired for the mouse tumour studies, and
100 000 cells for cervical tumour analyses.
Univariate histograms, plotted as cell number versus logarithm
of fluorescent antipimonidazole antibody intensity, were analysed
by a least-squares approach for 3 Gaussian distributions repre-
senting aerobic, intermediate, and hypoxic tumour cell popula-
tions. No constraints on the positions of the distribution means
were imposed. Therefore, the range but not absolute fluorescence
intensity determined whether a hypoxic fraction could be reliably
identified within cells from different tumours.
Analysis of hypoxic fraction using the comet assay
Single cells (20 000) from irradiated tumour cell suspensions were
embedded in 0.75% low gelling temperature agarose containing
2% dimethylsulphoxide and spread on agarose precoated micro-
scope slides. Slides were carefully submersed in an alkaline, high
salt lysing solution as previously described (McLaren et al, 1997).
Following lysis and rinse in alkali, slides were electrophoresed in
alkali at 0.6 volts cm–1 for 25 min, and then stained for 20 min in
2.5 µ g ml–1 propidium iodide. For each sample, approximately 400
individual cells or ‘comets’ were observed using a Zeiss epi-
fluorescence microscope and image analysis system (Olive et al,
1990). DNA damage was quantified as an increase in tail moment,
an indicator of damage that is proportional to the number of strand
breaks per cell. Tail moment was defined as the product of the
percent of DNA (fluorescence) in the tail and the distance between
the means of the head and tail fluorescence distributions.
For comet analysis of hypoxic fraction, frequency histograms
for tail moment were used to calculate hypoxic fraction. An itera-
tive fitting technique, independent of the amount of DNA damage,
was used to determine the size and position of the two normal
distributions representing the aerobic and hypoxic populations.
The displacement between the aerobic and hypoxic peaks was
constrained to fall between 1.9 and 3, and a free fit to the data was
performed using a least squares approach (Olive et al, 1997).RESULTS
SCCVII tumour cells from air-breathing mice were analysed for
pimonidazole binding with a FITC-conjugated monoclonal anti-
body using a bivariate presentation of DNA content versus log
pimonidazole content (Figure 1). The diploid normal cell popula-
tion is clearly visible in this tetraploid mouse tumour. These
normal cells were primarily resident macrophages, with a hypoxic
fraction similar to that of the tumour cells (Olive, 1989). The
analysis of pimonidazole binding in the SCCVII tumour was
confined to the tetraploid tumour cell population, a procedure that
was also adopted for comet analysis. However, it is apparent from
the continuum of pimonidazole intensities seen in Figure 1 that
simply setting a ‘threshold’ intensity to measure hypoxic fraction
is highly subjective.
At least a 100-fold range in fluorescence intensity was observed
for pimonidazole binding in SCCVII tumours (Figures 1, 2). In air-
breathing mice, most of the tumour cells were low in fluorescence
intensity, however, for mice breathing 10% oxygen during expo-
sure to pimonidazole, there was a shift in average intensity to
much higher values (Figure 2, upper panels). Most of the cells
were brightly fluorescent when mice were injected intraperi-
toneally (i.p.) with hydralazine 15 min after i.p. injection of
pimonidazole. Although hydralazine and clamping of the tumour
will trap drug in the tumour and reduce subsequent access to the
drug from plasma, there was little change in the average fluores-
cence of the hypoxic cells. The middle row in Figure 2 illustrates
our objective curve-fitting procedure, where we used an uncon-
stricted best fit of three Gaussian distributions representing
aerobic, intermediate and hypoxic populations. The mean fluores-
cence of the aerobic distribution was on average 10.8 ± 0.95 (mean
± SE, n = 43) times lower than the mean of the hypoxic distribu-
tion, although there was a trend for this ratio to increase for low
hypoxic fractions and decrease for high hypoxic fractions.
Sufficient differences in staining intensity between aerobic and
hypoxic cells to justify the use of the fitting procedure were typi-
cally seen for pimonidazole concentrations exceeding 30 mg kg–1.
Pimonidazole binding and comet assay 1527
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Figure 1 Analysis of pimonidazole binding in an SCCVII tumour. A C3H
mouse bearing a 400 mg SCCVII squamous cell carcinoma was injected
intraperitoneally with 100 mg kg–1 pimonidazole. 90 minutes later, the tumour
was excised, and a single cell suspension was prepared. Single cells were
fixed in 70% alcohol, then incubated with FITC-conjugated monoclonal
antibody against pimonidazole, and DNA was stained with DAPI. Panel (A)
shows the bivariate plot of DNA content versus pimonidazole binding. The
square delineates the tetraploid tumour cell population that is shown in the
histogram in panel (B)
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Figure 2 Representative data from 3 SCCVII tumours analysed for
pimonidazole binding and DNA damage. The upper curves show the
distributions of anti-pimonidazole antibody binding in tumours from a mouse
breathing air, 10% oxygen in nitrogen, or treated with hydralazine to reduce
tumour blood flow. A fitting program was used to describe 3 normally
distributed populations representing aerobic, intermediate and hypoxic
tumour cells. The percentage of hypoxic cells is shown in the middle panels.
For the same tumours, cells were analysed for hypoxic fraction using the
comet assay that detects the difference in radiation-induced strand breaks
between aerobic and radiobiologically hypoxic tumour cells. The percentage
of hypoxic cells is given in each panel1528 PL Olive et al
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For each tumour cell suspension, the comet assay was also used
to measure the fraction of radiobiologically hypoxic cells (Figure
2, lower panels). For this measurement of hypoxia, tumours were
exposed to radiation 90 min after injection of pimonidazole. This
length of time was found to be adequate to reduce parent drug
levels and thereby minimize any DNA breaks in hypoxic cells
caused by pimonidazole radiosensitization. In control experi-
ments, no DNA breaks by these tracer levels of pimonidazole were
observed. Agreement between the two methods for quantifying the
hypoxic population was best when the population with interme-
diate levels of antibody staining was not included in the pimonida-
zole hypoxic fraction.
To examine the reproducibility and sensitivity of the pimonida-
zole curve-fitting method for detecting hypoxic cells, aerobic or
anoxic cells were incubated for 90 minutes with 20 µ g ml–1
pimonidazole, and then mixed together in given proportions, fixed
in ethanol, and analysed for pimonidazole adducts (Figure 3).
Anoxic cells were identified to a detection limit of 0.5% when 
20 000 cells were analysed. Qualitatively similar results were
obtained when cells were incubated with a 4-fold lower concentra-
tion of pimonidazole, but the detection limit decreased to 2%. The
variability between samples is indicated by the plotted standard
deviation for 4 measurements obtained from the same fixed cell
mixture separated into individual samples for antibody binding
and analysis. When analysis was delayed until 10 days after either
fixation or even antibody labelling, the proportion of hypoxic cells
was not significantly different (data not shown). Therefore repro-
ducibility appears to be excellent and is unaffected by holding
samples for several days after preparation.
Although it was not possible to verify directly that the cells that
bound pimonidazole were the hypoxic cells in the tumour, the
location of the pimonidazole positive cells relative to the blood
supply could be examined with the expectation that cells distant
from the functional blood vessels were likely to be hypoxic.
Tumour cell subpopulations with different hypoxic fractions were
sorted on the basis of a Hoechst 33342 fluorescence gradient
produced after injection of this DNA stain into the tail vein of the
mouse. As previously observed for tumours labelled in air-
breathing mice (Durand and Raleigh, 1998), cells containing the
highest concentrations of Hoechst 33342 (i.e., closest to blood
vessels) showed the least amount of pimonidazole binding, and
cells with the lowest concentrations of Hoechst (i.e., distant from
the blood supply) bound the most pimonidazole (Figure 4).
A comparison between hypoxic fraction measured using the
comet assay and hypoxic fraction measured using pimonidazole
marker binding in the same SCCVII tumours is shown in 
Figure 5. The two methods were highly correlated for hypoxia.
Interestingly, carbogen breathing did not produce a significant
decrease in tumour hypoxic fraction relative to air-breathing. This
is likely to be explained by the long carbogen breathing period
(90 min) necessary for the pimonidazole binding studies.
Although carbogen may initially reduce tumour hypoxic fraction,
an extended breathing period (i.e., more than about 15 min) may
counteract this effect for some tumour types (Falk et al, 1992; Hill
et al, 1998).
Since pimonidazole binding is cell line dependent (Durand and
Raleigh, 1998), the applicability of the pimonidazole curve-fitting
analysis was also examined in two human tumour xenografts
known to bind less pimonidazole on average than SCCVII. SiHa
cervical carcinoma and U87 gliomas were used at tumour sizes
containing about 20% and 9% hypoxic cells, respectively. Results
for individual SCCVII tumours, as well as for the U87 and SiHa
xenograft tumours are combined in Figure 6, indicating that the
objective flow histogram analysis method is also applicable to
human tumour xenografts.
In our first clinical evaluations, 3 patients with cervical carci-
noma were given an intravenous infusion of 0.5 g m–2 pimonida-
zole approximately 24 hours before tumour excision biopsy.
Single cells obtained from these biopsies were subsequently
analysed for hypoxic fraction using the objective flow cytometry
method. Results shown in Figure 7 indicate hypoxic fractions
ranging from 2.7% to 8.3%.
DISCUSSION
Pimonidazole binding to hypoxic cells has been shown to be an
effective way to identify hypoxic regions within solid tumours
(Kennedy et al, 1997; Thrall et al, 1997; Durand and Raleigh,
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Figure 3 Analysis of hypoxic cells in known mixtures using the flow
cytometry method. Chinese hamster V79 cells were incubated in medium
equilibrated with air or nitrogen containing 20 µ g ml–1 pimonidazole. After a
90 min incubation, cells were recovered, mixed in various proportions, and
fixed in ethanol. Three days later, samples were analysed for pimonidazole
adducts using flow cytometry. Panel (A) is a representative histogram for a
mixture containing 46% hypoxic cells. Panel (B) shows the measured hypoxic
fraction plotted versus the known hypoxic fraction for 4 samples per mixture
(mean ± SD). The linear best-fit curve is shown, and the point on the y-axis
shows the results for 0% hypoxic cells1998; Varia et al, 1998; Raleigh et al, 1999). However, the degree
of hypoxia associated with the pimonidazole labelled areas has not
been well defined. For example, in the C3H mouse mammary
carcinoma, a comparison was made between pimonidazole
binding and two measures of tumour hypoxia: oxygen micro-
electrode measurements, and radiobiological hypoxic fraction as
measured using a clamped tumour control endpoint (Raleigh et al,
1999). For both of these comparisons, only 30% of the tumour area
was considered positive for pimonidazole binding, in spite of
the fact that 100% of the tumour cells were radiobiologically
Pimonidazole binding and comet assay 1529
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Figure 4 Analysis of the response of tumour cells recovered from different regions of an SCCVII tumour from a mouse breathing 10% oxygen in nitrogen. The
mouse was injected intraperitoneally with 100 mg kg–1 pimonidazole, and 90 min later given an intravenous injection of 8 mg kg–1 Hoechst 33342 to stain cells
close to the vasculature. The single cell suspension prepared from this tumour was sorted on the basis of the Hoechst 33342 diffusion gradient into 5 equal
fractions representing cells distant from the blood vessels (Hoechst dimmest) to cells closest to the blood vessels (Hoechst brightest). The percentage of cells
calculated as hypoxic, based on the 3 population fit, is given in each panel
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Figure 5 Comparison between pimonidazole marker binding and comet
assay for 45 SCCVII tumours. Tumours from mice breathing various gas
mixtures, mice treated with hydralazine, or tumours that were clamped
20 min after pimonidazole injection, were compared for hypoxic fraction
measured using pimonidazole binding, or by comet assay. The means and
standard errors are shown
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Figure 6 Comparison between pimonidazole marker binding and comet
assay for SCCVII tumours, U87 glioma xenograftsand SiHa cervical
carcinoma xenografts. Results for individual tumours are shown, and the
slope and correlation coefficient for the linear best-fit for all of the tumours are
shown1530 PL Olive et al
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hypoxic or 100% of oxygen electrode measurements fell below 10
mmHg. Possible reasons for these underestimates have been
discussed (Raleigh et al, 1999) and include lack of correction for
necrotic regions in tumour sections, possible inability of
pimonidazole to detect cells intermediate in oxygenation that still
contribute to radiation resistance, or variable influence of intermit-
tent changes in tumour perfusion on these different methods. In the
present study, a direct comparison between the response of the
single cells recovered from these tumours has shown a much
stronger correlation between radiobiologic hypoxia and pimonida-
zole binding. In flow analysis, necrotic cells and normal diploid
cells can be omitted from analysis, which should improve the
correlation. An important advantage of this method over the comet
assay is the ability to analyse tens of thousands of cells very
rapidly, and thus identify small hypoxic fractions with more
certainty. In attempting to estimate the sensitivity of the method
for detecting hypoxic cells (Figure 3), an important issue is the
number of cells analysed. Resolution will increase as the number
of cells analysed increases. Rather than attempting to use absolute
intensity for quantitation, flow analysis can make use of range in
fluorescence intensity, or the percentage of cells above a back-
ground level of staining. This should avoid problems associated
with variable drug delivery and differences in rate of drug metabo-
lism.
A perceived problem with oxygen electrode measurements is
that the relation between tumour pO2 and radiobiologic hypoxia
can vary for different murine tumour types (Horsman et al, 1994).
Similarly, differences in rate of metabolism of pimonidazole
between tumour types can lead to differences in rate of pimonida-
zole binding (Durand and Raleigh, 1998) and although clamping
tumours can trap pimonidazole, it also reduces availability and
causes less total pimonidazole to be bound. An important advant-
age of single cell analysis is that it provides information on the
range of binding, and as indicated above, this range is what is
critical for determining hypoxic fraction. Even though individual
SiHa, SCCVII and U87 glioma tumours bound different absolute
amounts of pimonidazole, the hypoxic fraction determined using
the histogram-fitting method was found to be a useful measure of
radiobiological hypoxic that was independent of differences in 
rate of pimonidazole binding between these tumour types. These
results provide confidence that the flow cytometry method for
evaluating hypoxia marker binding would also be applicable to
cells from human tumours. A comparison was previously
performed between the comet assay and binding of another
hypoxia marker, EF5 (Kavanagh et al, 1999). These authors used
an arbitrary factor of 10 times the background mean fluorescence
as a cut-off to define the hypoxic cells of the tumour, and although
the correlation between the comet assay and EF5 binding was very
good, a comparison between both methods using the same cell
suspension was not provided.
There are several ways to assess the sensitivity of the method
for detecting hypoxic cells. From the slope and confidence limits
shown in Figure 5, a value of about 5% hypoxia appears to repre-
sent the limit of sensitivity. However, errors associated with both
pimonidazole staining and comet assay are included in this
analysis, and the errors associated with the comet assay are larger
than those associated with pimonidazole binding, at least for the
lower hypoxic fractions (Figure 4). A more direct way of deter-
mining sensitivity of the pimonidazole binding method is by
analysing flow histograms from known mixtures of aerobic and
hypoxic cells. This analysis indicated that it could be possible to
detect hypoxic fractions as low as 0.5%. However, mixtures of
cultured cells used in Figure 3 represent an optimum situation that
is unlikely to occur with heterogeneous samples obtained from
human tumours. While the reproducibility of the method is excel-
lent for multiple samples analysed from the same population, a
larger error is associated with the curve-fitting programme itself.
A comparison was made between results obtained independently
by two investigators analysing 10 histograms from tumours that
contained 3% to 95% hypoxic cells. While both investigators
agreed on the percentage of aerobic cells in the samples (r2 = 0.99,
slope = 0.87), the percentage of cells defined as hypoxic or inter-
mediate was more variable when hypoxic fractions exceeded 0.2.
Modifications to the analysis programme to ensure similar CVs for
the aerobic and hypoxic populations, and to maintain a 10-fold
differential between the mean fluorescence of the aerobic and
hypoxic populations should reduce this variability.
The 3 examples of pimonidazole-binding patterns in human
tumours indicated a mean percentage of hypoxic cells of 5.3%.
This value compares well with previous analysis of pimonidazole
binding in tumour sections; the percentage of tumour sections
from 13 cervical tumours that were labelled with pimonidazole
averaged 4.3%, with a range of 0–25.8% (Raleigh et al, 1998).
This average hypoxic fraction measured by pimonidazole binding
can be compared to a mean oxygenation of about 10 mmHg for
cervical tumours (Fyles et al, 1998), or a mean hypoxic fraction of
0.15 for a variety of tumour types analysed after radiation expo-
sure using the comet assay (Olive et al, 1999).
In conclusion, comparison of results obtained using the comet
assay with pimonidazole binding for the same tumour samples has
provided an aid to interpret pimonidazole marker binding. The
criteria used to define hypoxic cells by pimonidazole binding in a
murine tumour were also applicable to two human tumour
xenografts. Results obtained from cervical tumours from 3
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Figure 7 Flow cytometry analysis of hypoxic fraction in cervical cancer cells
from patients given 0.5 g m–2 pimonidazole 24 hours prior to excision biopsy.
The percentage of hypoxic cells derived from the curve-fitting programme is
shownPimonidazole binding and comet assay 1531
British Journal of Cancer (2000) 83(11), 1525–1531 © 2000 Cancer Research Campaign
patients administered pimonidazole confirm that the method can
be applied to single cells from excision biopsies, and an estimate
of hypoxic fraction can be available on the day of biopsy. We are
currently comparing this flow cytometry method with analysis of
tumour sections from the same patient and with oxygen micro-
electrode measurements.
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